Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 162
Filter
1.
Braz. dent. j ; 31(6): 634-639, Nov.-Dec. 2020. tab, graf
Article in English | LILACS, BBO | ID: biblio-1132353

ABSTRACT

Abstract Micro-RNA-221(miR-221) is one of oncogenic miRNAs that plays a vital role in the development and progression of oral cancers. The aim of this study is to introduce a new gene therapy for oral squamous cell carcinoma by blocking the expression of oncogenic miR-221 by its inhibitor. The present work was performed on squamous cell carcinoma cell line SCC-25 and anti-miR-221 was delivered to the cells using an ultrasound micro bubbles. Assessment of the effect of miR-221 inhibitor on SCC-25 cells was done using MTT assay, cell cycle analysis and apoptosis detection. In addition, reverse transcription-polymerase chain reaction was also used to detect the expression -miR-221 and its target genes. Using ANOVA, statistical analysis of the results showed significant inhibition of cell viability with and induction of cell apoptosis of SCC-25 cell line after transfection. Moreover, the expression of miR-221, Epidermal growth factor receptor (EGFR) and CDKNIB/p27 were downregulated without significant difference. Transfection of SCC-25 by inhibitor of miR-221 resulting in blockage of its expression leading to arresting of tumor growth. These results proved the effective role of micro-RNA inhibitors as novel therapeutic agent for oral cancers.


Resumo Micro-RNA-221 (miR-221) é um dos miRNAs oncogênicos que desempenham um papel vital no desenvolvimento e progressão de carcinomas orais. O objetivo deste estudo é apresentar uma nova terapia gênica para o carcinoma epidermóide oral por meio do bloqueio da expressão do miR-221 oncogênico por seu inibidor. O presente trabalho foi realizado na linhagem de células de carcinoma de células escamosas SCC-25 e o anti-miR-221 foi administrado às células usando micro-bolhas de ultrassom. A avaliação do efeito do inibidor miR-221 em células SCC-25 foi feita usando ensaio de MTT, análise do ciclo celular e detecção de apoptose. Além disso, a reação em cadeia da polimerase com transcrição reversa também foi usada para detectar a expressão -miR-221 e seus genes-alvo. Usando ANOVA, a análise estatística dos resultados mostrou inibição significativa da viabilidade celular e indução da apoptose celular da linhagem celular SCC-25 após a transfecção. Além disso, a expressão de miR-221, receptor do fator de crescimento epidérmico (EGFR) e CDKNIB/p27 foram regulados para baixo sem diferença significativa. A transfecção de SCC-25 por inibidor de miR-221 resultou no bloqueio de sua expressão, levando à interrupção do crescimento do tumor. Esses resultados comprovaram o papel eficaz dos inibidores de micro-RNA como novo agente terapêutico para carcinomas orais.


Subject(s)
Humans , Mouth Neoplasms/genetics , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/therapy , MicroRNAs/antagonists & inhibitors , MicroRNAs/genetics , MicroRNAs/therapeutic use , Mouth Neoplasms/therapy , Genetic Therapy , Apoptosis , Cell Line, Tumor , Cell Proliferation
2.
Rev. argent. coloproctología ; 31(1): 21-27, mar. 2020. tab
Article in Spanish | LILACS | ID: biblio-1102171

ABSTRACT

Introducción: El tratamiento del carcinoma anal escamoso (CAE) en los pacientes HIV positivos resulta controvertido. Si bien las guías actuales recomiendan realizar en los pacientes con buen estado inmunológico la quimiorradioterapia (QRT) concurrente estándar, algunos autores consideran que estos pacientes presentan mayor toxicidad y peores resultados a largo plazo, por lo que requerirían un abordaje diferente. El objetivo de este trabajo es comparar los resultados del tratamiento del CAE en los pacientes VIH positivos y negativos. Diseño: Estudio retrospectivo comparativo. Pacientes y métodos: Se revisaron retrospectivamente las historias clínicas de los pacientes tratados en el Sector Coloproctología, Hospital Fernández, entre 01/2007 y 10/2018. Los del conducto anal se dividieron en: Grupo I: VIH negativos y Grupo II: VIH positivos. Se compararon variables demográficas, factores de riesgo específicos, estadificación, QRT (drogas, toxicidad y respuesta), tratamiento quirúrgico curativo/paliativo, persistencia/recurrencia y supervivencia específica y global. Resultados: Se incluyeron 28 pacientes (18 mujeres); margen: 2, conducto: 26 (Grupo I: 15. Grupo II: 11). Los VIH positivos eran en su mayoría hombres que tienen sexo con hombres vs. 100% de mujeres VIH negativas (p<0,01), más jóvenes (45,2±0,9 vs. 63,6±8; p<0,01) y tabaquistas (82% vs. 27%; p=0,005). No hubo diferencia significativa en la estadificación, aunque el Grupo II tuvo tumores con complicaciones más severas. Pudieron completar el tratamiento: Grupo I: 93%, Grupo II: 64% (p<0,05). Tuvieron respuesta completa a la QRT 13/14 (93%) pacientes del Grupo I y 3/7 (43%) del Grupo II (p<0,01). Hubo 3 recurrencias, 2 locorregionales y 1 a distancia (p=NS). Los VIH positivos requirieron más cirugías (82% vs. 27%; p<0,01). A 5 pacientes (4 del Grupo II) se les realizó una resección abdominoperineal (RAP). Tuvieron colostomía definitiva, con o sin RAP, el 46% de los pacientes, la mayoría VIH positivos (82% vs. 27%; p=0,002). En los VIH positivos el RR de mortalidad por cáncer fue 4 (IC95%: 1,01-16,5; p=0,02) y el RR de mortalidad global fue 5,45 (IC95%: 1,42-20,8; p=0,002). Tuvieron menor supervivencia, tanto global (p=0,001) como libre de enfermedad (p=0,01). Mediana de seguimiento: 27 meses (4-216).Conclusiones: Los pacientes VIH positivos con CAE se diferenciaron de los VIH negativos en una menor tasa de respuesta completa a la QRT y una mayor necesidad de tratamiento quirúrgico. Además, tuvieron una supervivencia global y libre de enfermedad significativamente menor que los VIH negativos. (AU)


INTRODUCTION: The treatment of anal squamous cell carcinoma (SCC) in HIV-positive patients is controversial. Although current guidelines recommend performing standard concurrent chemoradiotherapy (CRT) in patients with good immune status, some authors believe that these patients have greater toxicity and worse long-term results, so they would require a different approach. The purpose of this study was to compare the results of SCC treatment in HIV-positive and HIV-negative patients.DESIGN: Comparative retrospective study.PATIENTS AND METHODS: The records of patients treated in the Coloproctology Section, Hospital Fernández, between 01/2007 and 10/2018 were retrospectively reviewed. Those of the anal canal were divided into: Group I: HIV-negative and Group II: HIV-positive. Demographic variables, specific risk factors, staging, CRT (drugs, toxicity, and response), curative/palliative surgical treatment, persistence/recurrence, and cancer-specific and global survival were compared.RESULTS: 28 patients (18 women), margin: 2, conduit: 26 (Group I: 15. Group II: 11). The HIV-positive were mostly men who have sex with men (vs. 100% HIV-negative women; p<0.01), younger (45.2 ± 0.9 vs. 63.6 ± 8; p<0.01) and smokers (82% vs. 27%; p=0.005). There was no significant difference in staging, although Group II had tumors with more severe complications. Completed the treatment: Group I: 93%, Group II: 64% of patients (p<0,05). Thirteen out of 14 (93%) patients in Group I, and 3/7 (43%) patients in Group II had a complete response to CRT (p<0.01). There were 3 recurrences, 2 loco-regional and 1 distance (p=NS). HIV-positive required more surgery (82% vs. 27%; p<0.01). 5 patients (4 of Group II) underwent an abdominal-perineal resection (APR). Forty six percent of patients had permanent colostomy, with or without APR, most of them were HIV-positive (82% vs. 27%; p=0.002). In HIV-positive patients, the RR of cancer mortality was 4 (95% CI: 1.01-16.5; p=0.02) and the RR of overall mortality was 5.45 (95% CI: 1.42-20, 8; p=0.002). They also had lower overall (p=0.001) and disease-free survival (p=0.01). Median follow-up: 27 months (4 - 216).CONCLUSION: HIV-positive patients with anal SCC were different from HIV-negative patients in that they had a lower complete response rate to CRT, and a greater need for surgical treatment. They had a significantly lower overall and disease-free survival than HIV-negative patients. (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Young Adult , Anus Neoplasms/therapy , Carcinoma, Squamous Cell/therapy , HIV Infections/complications , Chemoradiotherapy , Anus Neoplasms/surgery , Anus Neoplasms/complications , Anus Neoplasms/mortality , Carcinoma, Squamous Cell/surgery , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/mortality , Survival Analysis , Retrospective Studies , Treatment Outcome , Proctectomy , Neoplasm Recurrence, Local , Neoplasm Staging
3.
Braz. oral res. (Online) ; 34: e032, 2020. tab, graf
Article in English | LILACS | ID: biblio-1089384

ABSTRACT

Abstract About 92,000 new cases of oropharynx carcinoma are expected to occur annually worldwide. There is no consensus about the best therapy for these advanced tumors. The objective of the present study was to evaluate overall and disease-free survival rates of patients with advanced oropharynx squamous cell carcinoma, comparing surgery + radiotherapy with chemotherapy + radiotherapy. Medical records of patients were reviewed. Previously treated tumors were excluded. Clinical, demographic and microscopic information was collected, and p16 staining was performed. Kaplan-Meier survival curves were plotted. Forty-seven cases were included, 41 men and 6 women, having a mean age of 56.3 years. Most patients were smokers (85.1%) and consumed alcohol (74.5%). Patients were stage III (21.3%) or IV (78.7%). Most lesions affected the base of the tongue (36.2%). Of the 23 cases available for p16 testing, 3 were positive (13.0%). There was no difference between the overall and the disease-free survival rates for the two treatment modalities (p>0.05), even when only resectable tumors were compared. Seventeen cases experienced recurrence (36.2%); 16 (34.0%) patients remained alive without disease; 15 (31.9%) died due to disease; 9 (19.2%) were recurrent at the last follow-up. The two treatment protocols were equally efficient in treating advanced oropharynx squamous cell carcinoma, since both promoted similar overall and disease-free survival rates. The results and interpretations related herein mostly regard "conventional" oropharyngeal squamous cell carcinomas, as opposed to HPV-associated tumors.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/therapy , Oropharyngeal Neoplasms/mortality , Oropharyngeal Neoplasms/therapy , Time Factors , Cross-Sectional Studies , Treatment Outcome , Combined Modality Therapy , Disease-Free Survival , Kaplan-Meier Estimate , Middle Aged , Neoplasm Recurrence, Local
4.
Einstein (Säo Paulo) ; 18: eRC5409, 2020. graf
Article in English | LILACS | ID: biblio-1133733

ABSTRACT

ABSTRACT Percutaneous endoscopic gastrostomy is used to provide enteral nutritional support for patients with obstructive oropharyngeal or esophageal neoplasms. The placement of the catheter is considered safe, with few complications. Despite this, a specific complication that is considered rare, has been increasingly described in the literature, i.e., metastasis of head and neck cancer in the gastrostomy stoma. In this report, we described a case of metastasis of squamous cell carcinoma of the larynx in the gastrostomy site, and discussed the possible etiologies and alternatives, seeking to reduce the incidence of this complication.


RESUMO A gastrostomia endoscópica percutânea é utilizada para oferecer suporte nutricional enteral para pacientes com neoplasias obstrutivas de orofaringe ou esôfago. A colocação da sonda é considerada segura, com poucas complicações. Apesar disso, uma complicação em particular, considerada rara, está sendo cada vez mais descrita na literatura: a metástase de neoplasia de cabeça e pescoço para o estoma da gastrostomia. Neste relato, descrevemos um caso de metástase de carcinoma espinocelular de laringe para o sítio da gastrostomia, e discutimos as possíveis etiologias e alternativas, buscando diminuir a incidência desta complicação.


Subject(s)
Humans , Male , Stomach Neoplasms/secondary , Esophageal Neoplasms/pathology , Gastrostomy/adverse effects , Carcinoma, Squamous Cell/secondary , Oropharyngeal Neoplasms/pathology , Laryngeal Neoplasms/pathology , Head and Neck Neoplasms/pathology , Stomach Neoplasms/surgery , Carcinoma, Squamous Cell/therapy , Carcinoma, Squamous Cell/diagnostic imaging , Enteral Nutrition/adverse effects , Head and Neck Neoplasms/therapy , Middle Aged , Neoplasm Metastasis
5.
Rev. Odontol. Araçatuba (Impr.) ; 40(3): 34-37, set.-dez. 2019. graf, tab
Article in Portuguese | LILACS, BBO | ID: biblio-1102223

ABSTRACT

O carcinoma epidermoide de lábios tem suas manifestações clínicas iniciais como atrofia, ressecamento e fissuras do vermelhão do lábio inferior com margem indefinida entre o vermelhão e a pele. O diagnóstico precoce é de fundamental relevância nos casos dessa patologia. O cirurgião dentista tem um papel extremamente importante neste caso. Objetivo: Realizar uma revisão da literatura pertinente sobre o carcinoma epidermoide oral. Metodologia: Essa revisão foi realizada empregando a base de dados do SCIELO, LALICS e BBO - Odontologia, foram pesquisados artigos da literatura com língua inglesa e portuguesa publicados no período de 2013 a 2018 com auxílio dos termos: câncer oral, diagnóstico e fatores associados. Foram excluídos os artigos cujas abordagens antes de 2013, outras línguas as não citadas, teses, projetos e produções não relacionadas a temática. Resultados: Os métodos tradicionais de tratamento oncológico são: cirurgia, radioterapia e a quimioterapia. O tratamento a ser estabelecido estará na dependência da localização, grau histológico de malignidade, estadiamento do tumor e da condição de saúde do indivíduo. Conclusões: O cirurgião-dentista deve estar preparado para diagnosticar e lidar com pacientes que apresentam lesões cancerizáveis com o propósito de diminuir as taxas de incidência e mortalidade e, então, melhorar a qualidade de vida das pessoas(AU)


Cancer is a cellular modification that is related to the loss of its metabolic regulation and intercellular control in which it differs depending on its type and behaves, biologically, different from a normal cell. From this point of view, lower lip cancer is one of the most frequent manifestations of oral cancer. The most frequent risk factors are stimulated from the practice of harmful habits such as: exposure to sunlight, alcohol consumption and smoking. Squamous cell carcinoma of the lips has its initial clinical manifestations such as atrophy, dryness and fissures of vermilion of the lower lip with indefinite margin between the vermilion and the skin. Early diagnosis is of fundamental relevance in cases of this pathology. The dentist surgeon plays an extremely important role in this case. The traditional methods of cancer treatment are: surgery, radiotherapy and chemotherapy. The treatment to be established will depend on the location, histological grade of malignancy, tumor staging and the individual's health condition. Therefore, the dental surgeon must be prepared to diagnose and deal with patients who have cancerous lesions in order to reduce incidence and mortality rates and thus improve people's quality of life(AU)


Subject(s)
Lip Neoplasms , Carcinoma, Squamous Cell , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/therapy , Carcinoma, Squamous Cell/epidemiology
6.
Rev. argent. cir ; 111(3): 129-141, set. 2019. graf, tab
Article in Spanish | LILACS | ID: biblio-1057355

ABSTRACT

Antecedentes: sobre la base de la bibliografía revisada y los resultados de supervivencia global y libre de enfermedad con diferentes márgenes de resección, se plantea la hipótesis de que márgenes < 5mm son suficientes para lograr una tasa de supervivencia global y comparables a las obtenidas con márgenes mayores. Objetivo: evaluar la supervivencia global y la supervivencia específica a 3 y 5 años de los pacientes con carcinomas escamosos de cavidad oral, en función de los márgenes quirúrgicos obtenidos. Material y métodos: se reclutaron entre enero de 2010 y diciembre de 2017 81 pacientes operados, 57,1%hombres, con una edad media de 60,49 años. Resultados: en el análisis multivariado en función de la supervivencia global y libre de enfermedad, resultaron variables pronósticas significativas el grado de diferenciación tumoral (p = 0,033), la invasión ganglionar extracapsular (p = 0,001) y la infiltración perineural (p = 0,000). Se pudo observar que no hay diferencias en la supervivencia libre de enfermedad de los diferentes grupos evaluados sobre la base de los márgenes quirúrgicos, pero se cree que la radioterapia posoperatoria estaría confundiendo la importancia real de los márgenes, debido a que la mayoría de los pacientes que presentaban márgenes cercanos fueron sometidos a radioterapia posoperatoria. Conclusiones: las variables analizadas concuerdan con la bibliografía en el sentido de que los únicos factores pronósticos resultan las características histológicas. Si bien existen muchos trabajos que analizan los márgenes en el carcinoma escamoso de cavidad oral, todavía no hay consenso en cuanto al valor pronóstico de los márgenes cercanos (1-5 mm).


Background: Based on the literature reviewed and the results of overall and disease-free survival with different surgical margins, we hypothesized that margins < 5mm are sufficient to achieve and overall survival rate and are comparable to those obtained with larger margins. Objective: The primary outcome of the present study was to evaluate overall survival and specific survival at 3 and 5 years of patients with squamous cell carcinoma of the oral cavity according to the surgical margins obtained. Material and methods: Between January 2010 and December 2017, 81 patients underwent surgery; 57.1% were men and mean age was 60.49 years. Results: At multivariate analysis, tumor differentiation (p = 0.033), extracapsular lymph node invasion (p = 0.001) and perineural invasion (p = 0.000) were identified as significant predictors of overall survival and disease-free survival. There were no differences in disease-free survival in the different groups evaluated based on the surgical margins. Yet, postoperative radiotherapy may actually obscure the importance of margins since most patients with close margins underwent postoperative radiotherapy. Conclusions: The variables analyzed in this paper are consistent with the literature in that only histological characteristics are prognostic factors. Although there are many studies analyzing the surgical margins in squamous carcinoma of the oral cavity, there is still no consensus regarding the prognostic value of close margins (1-5 mm).


Subject(s)
Humans , Male , Middle Aged , Aged , Mouth Neoplasms/surgery , Carcinoma , Carcinoma, Squamous Cell/therapy , General Surgery , Methods , Mouth , Neoplasms
7.
Salud pública Méx ; 61(3): 329-338, may.-jun. 2019. graf
Article in English | LILACS | ID: biblio-1094471

ABSTRACT

Abstract: Objective: To review the state-of-the-art in relation to the current information on squamous cell lung cancer (SCLC). We describe the genetic anomalies reported, their effect, and finally the most promising therapeutic agents. Materials and methods: We reviewed published articles in peer-reviewed journals as well as current treatment guidelines from local and international resources. Results: SCLC represents a smaller proportion of the global burden of disease for lung cancer compared to its more frequent presentation, the adenocarcinoma. However, more than 400 000 cases are reported annually, a substantial population for whom therapeutic options are scarce and with limited efficacy. Several groups have been given the task of elucidating the mechanisms that lead to the development of SCLC, including molecular anomalies that can be used as targets for drug design. Conclusion: There are potential therapeutic targets for SCLC, which must be studied in clinical trials for validation.


Resumen: Objetivo: Revisar el estado del arte en relación con la información actual sobre el cáncer de pulmón de células escamosas (CPCE) y describir las anomalías genéticas reportadas, su efecto y los agentes terapéuticos más prometedores. Material y métodos: Se realizó una revisión de artículos publicados en revistas indizadas, así como las guías de tratamiento publicadas por instancias locales e internacionales. Resultados: El CPCE representa una proporción menor de la carga mundial de la enfermedad por cáncer pulmonar en comparación con su presentación más frecuente, el adenocarcinoma. Sin embargo, más de 400 000 casos son reportados anualmente, una población sustancial para quienes las opciones terapéuticas son escasas y con una eficacia limitada. Diversos grupos se han dado a la tarea de elucidar los mecanismos que conllevan al desarrollo del CPCE, incluyendo anomalías moleculares que puedan servir como blancos para el diseño de fármacos. Conclusiones: Existen blancos terapéuticos potenciales para el CPCE que deben ser estudiados en ensayos clínicos para ser validados.


Subject(s)
Humans , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/therapy , Precision Medicine , Lung Neoplasms/genetics , Lung Neoplasms/therapy , Genomics
8.
São Paulo; s.n; 2019. 157 p. ilust, tabelas.
Thesis in Portuguese | LILACS, Inca | ID: biblio-1222818

ABSTRACT

Introdução: O papel prognóstico de células tumorais circulantes (CTCs) em câncer de cabeça e pescoço localmente avançado (CCPLA) ainda não está determinado, devido a resultados conflitantes em estudos prévios, a maioria utilizando técnicas dependentes de citoqueratina para identificação e contagem de CTCs. O objetivo primário deste estudo é determinar a taxa de detecção utilizando o método ISET, o papel prognóstico e potencial papel preditivo de CTCs em CCPLA. Métodos: Prospectivamente amostras de sangue de pacientes com CCPLA não metastático, estágios III/IV, foram analisadas para CTCs antes e após o tratamento, em dois cenários: cirurgia curativa inicial e radioterapia (RT) adjuvante e candidatos a estratégia não cirúrgica (irressecáveis ou preservação de órgão) com RT concomitante a quimioterapia (QT) ou cetuximabe, precedida ou não por QT de indução (QTI). Resultados: Foram incluídos 83 pacientes e a taxa de detecção de CTCs baseline foi de 94% (78/83). A contagem de CTCs se correlacionou significativamente com sobrevida, com um aumento relativo de 18% no risco de óbito (HR=1,18; CI95%: 1,06-1,31; p<0,001), 16% no risco de progressão (HR=1,16; CI95%: 1,04-1,28; p=0,004) e uma redução de 26% na chance de resposta completa ao tratamento (OR=0.74; CI95%: 0.58-0.95; p=0.022) para cada aumento de uma CTC. Pacientes com CTCs < 6,5/mL apresentaram estimativa de sobrevida global (SG) em dois anos de 85,6% x 22,9% para CTCs ≥ 6.5/mL (HR=0,18; CI95%: 0,06-0,49; P<0,0001) e pacientes com CTCs ≤ 3.8/mL uma estimativa de sobrevida livre de progressão (SLP) em dois anos de 71,8% x 37% para CTCs > 3.8/mL (HR=0,32; CI95%:0,15-0,67; p=0,001). Após o tratamento, contagens altas de CTCs (ponto de corte 6,6/mL) se correlacionaram significativamente com pior SG (HR=0,12; CI95%: 0,06-0,40; p<0,001) e SLP (HR=0,19; CI95%: 0,06-0,59; p=0,001). No subgrupo de tratamento não cirúrgico (n=67), presença de microêmbolos (ME) se correlacionou significativamente com pior SG (HR=3,01; CI95%: 1,06-8,52; p=0,029) e SLP (HR=3,84; CI95%: 1,62-9,11; p<0,001). Neste subgrupo, CTCs altas (>3,8/mL) e ME foram identificados como potenciais preditores do benefício de QTI. Expressão de MRP-7 em ME baseline se relacionou a pior SG (HR=3,49; CI95%: 1,01-12,04; p=0,047) e SLP (HR=3,62; CI95%: 1,08-12,13; p=0,037) e expressão de TFGßRI nas CTCs após o tratamento a pior SG (HR=3,60; 1,03-12,59; p=0,032). Expressão de ß-tubulina III nas CTCs se relacionou a pior SG em pacientes recebendo QTI (p=0.012). Pacientes com cinética favorável de CTCs tiveram melhor SG (HR=0,22; IC95%: 0,07-0,67; p=0,004) e SLP (HR=0,33; CI95%: 0,13-0,84; p=0,015). Conclusões: Contagem de CTCs baseline se correlacionaram com sobrevida e resposta ao tratamento e, junto com ME, são potenciais fatores preditivos do benefício de QTI. Contagens de CTCs altas após o tratamento e cinética desfavorável também foram prognósticos. Expressão de biomarcadores em CTCs e ME tem papel prognóstico e preditivo em CCPLA


Introduction: The prognostic role of circulating tumor cells (CTCs) in locally advanced head and neck squamous cell carcinoma (LAHNSCC) is yet to be determined, with conflicting results in previous trials, the majority utilizing cytokeratin dependent techniques for identification and counting of CTCs. The primary objective of this study is to determine the detection rates using the ISET method, the prognostic and potential predictive role of CTCs in LAHNSCC patients (pts) treated with a curative intent. Methods: In this prospective study, peripheral blood samples of pts with non-metastatic LAHNSCC, stages III/IV, were analyzed for CTCs before and after treatment, in two scenarios: curative surgical resection and adjuvant radiotherapy (RT) and candidates for a non-surgical strategy (unresectable or organ preservation) with RT concurrent with chemotherapy (CT) or cetuximab, preceded or not by induction CT (ICT). Results: Eighty-three pts were included, and the detection rate of baseline CTCs was 94% (78/83). The CTCs counts were significantly correlated with survival, with an a relative increase of 18% in the risk of death (HR=1.18; CI95%: 1.06-1.31; p<0.001), 16% in the risk of progression (HR=1.16; CI95%: 1.04-1.28; p=0.004) and a reduction of 26% in the odds of complete response to treatment (OR=0.74; CI95%: 0.58-0.95; p=0.022) for each increase of one CTC. Pts with CTCs < 6,5/mL had an estimated two year overall survival (OS) of 85.6% x 22.9% for CTCs ≥ 6.5/mL (HR=0.18; CI95%: 0.06-0.49; P<0.0001) and pts with CTCs ≤ 3.8/mL had an estimated two year progression free survival (PFS) of 71.8% x 37% for CTCs > 3.8/mL (HR=0.32; CI95%:0.15-0.67; p=0.001). After treatment, high CTCs counts (cut-off 6,6/mL) were significantly correlated with worse OS (HR=0.12; CI95%: 0.06-0.40; p<0.001) and PFS (HR=0.19; CI95%: 0.06-0.59; p=0.001). In the non-surgical subgroup (n=67), the presence of microemboli (ME) was correlated with a significantly worse OS (HR=3.01; CI95%: 1.06-8.52; p=0.029) and PFS (HR=3.84; CI95%: 1.62-9.11; p<0.001). In this subgroup, high CTCs counts (>3,8/mL) and ME were identified as potential predictive factors for efficacy of ICT. Baseline expression of MRP-7 in ME was related to a worse OS (HR=3.49; CI95%: 1.01-12.04; p=0.047) and PFS (HR=3.62; CI95%: 1.08-12.13; p=0.037) and TFGßRI expression in CTCs after treatment to a worse OS (HR=3.60; 1.03-12.59; p=0.032). ß-tubulin III expression in CTCs was related to a worse OS in pts receiving ICT (p=0.012). Patients with favorable kinetics of CTCs had better OS (HR=0.22; IC95%: 0.07-0.67; p=0.004) and PFS (HR=0.33; CI95%: 0.13-0.84; p=0.015). Conclusions: Baseline CTCs counts were correlated with survival and response to treatment and, along with ME, potential predictive factors of ICT benefit. High CTCs counts after treatment and unfavorable kinetics were also prognostic. Biomarker expression in the CTCs and ME have prognostic and predicitive role in LAHNSCC


Subject(s)
Humans , Male , Adult , Middle Aged , Aged , Carcinoma, Squamous Cell/therapy , Biomarkers, Tumor , Head and Neck Neoplasms , Neoplastic Cells, Circulating
9.
Rev. cuba. oftalmol ; 31(4): 88-92, oct.-dic. 2018. ilus
Article in Spanish | LILACS | ID: biblio-991117

ABSTRACT

El dellen corneal es un área de adelgazamiento corneal localizado como consecuencia de la deshidratación provocada por la falta de humectación relacionada con una zona adyacente de abultamiento conjuntival. Se presenta una paciente femenina de 72 años, blanca, con antecedentes de hipertensión arterial, quien refirió lagrimeo y sensación de cuerpo extraño en el ojo izquierdo, de una semana de evolución. Al examen biomicroscópico se observó tejido fibrovascular en conjuntiva bulbar nasal que infiltraba la córnea, sobreelevado, de superficie lisa, no queratinizada, acompañada de inyección conjuntival y múltiples neovasos. En la córnea periférica y adyacente a esta se observó depresión de base limpia, redondeada, de 6 mm de extensión y profundidad hasta estroma anterior. Teniendo en cuenta las características de la lesión, se planteó como diagnóstico presuntivo dellen corneal secundario a pterigium grado II sintomático. La biopsia informó carcinoma de células escamosas, moderadamente diferenciado, asociado con un extenso infiltrado inflamatorio a predominio de linfocitos(AU)


Corneal dellen is an area of localized corneal thinning as a result of dehydration caused by lack of humectation associated to an adjoining conjunctival bulging. Here is a 72-years old Caucasian woman with a history of hypertension, who presented continuous tearing and feeling of a foreign body in her left eye during a week. The biomicroscopic exam showed fibrovascular tissue in nasal bulb conjunctiva, which infiltrated into the cornea, it was raised of flat surface, unkeratinized, accompanied with conjunctival injection and multiple neovessels. In the peripheral cornea and adjacent to it, there was a clean, rounded depression measuring 6 mm of extension and depth up to the anterior stroma. The presumptive diagnosis was corneal dellen secondary to symptomatic grade II pterygium. The biopsy yielded the presence of squamous cell carcinoma, moderately differentiated, and associated with extensive inflammatory infiltrate with predominance of lymphocytes(AU)


Subject(s)
Humans , Female , Aged , Carcinoma, Squamous Cell/therapy , Conjunctival Diseases/drug therapy , Corneal Stroma/injuries , Cryotherapy/methods
10.
Int. arch. otorhinolaryngol. (Impr.) ; 22(4): 395-399, Oct.-Dec. 2018. tab, graf
Article in English | LILACS | ID: biblio-975602

ABSTRACT

Abstract Introduction Critical weight loss is defined as an unintentional weight loss of ≥ 5% at 1 month or ≥ 10% at 6 months from the start of treatment. Critical weight loss leads to deterioration of the immune function and reduced tolerance to treatment (surgery ± radiochemotherapy) as well as increased complication rates. Objective Critical weight loss, defined as a weight loss of ≥ 5% after 1 month or ≥ 10% after 6 months from the start of treatment, is not uncommon in head and neck cancer patients. We aimed to assess the factors associated with critical weight loss during the treatment of oral cavity squamous cell carcinoma patients. Methods A retrospective cohort study was performed at the Aga Khan University Hospital, in Karachi, Pakistan, on 125 patients. Patients receiving adjuvant therapy were considered exposed, and the outcome was critical weight loss. Results The mean age of presentation was 46.9 ± 12.8 years in patients undergoing surgery and adjuvant therapy, with 119 (79.3%) of them being male and 31 (20.7%) female. One hundred and twelve patients (81.3%) developed critical weight loss at 6 months from the start of treatment, and the only significant variable associated with critical weight loss was the stage of the disease (p= 0.03). Conclusion A large proportion of patients with oral cancer developed critical weight loss requiring a need for intervention. The overall stage of the disease is a significant predictor of critical weight loss in patients undergoing treatment.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Mouth Neoplasms/complications , Carcinoma, Squamous Cell/complications , Weight Loss , Neck Dissection , Mouth Neoplasms/therapy , Carcinoma, Squamous Cell/therapy , Retrospective Studies , Risk Factors , Cohort Studies , Enteral Nutrition , Malnutrition/etiology , Diet , Chemoradiotherapy, Adjuvant
11.
Rev. méd. Chile ; 146(12): 1438-1443, dic. 2018. tab, graf
Article in Spanish | LILACS | ID: biblio-991354

ABSTRACT

Background: Gallbladder epidermoid carcinoma is rare and more common in women over 55 years of age. Aim: To report the features of 15 patients with gallbladder epidermoid carcinoma. Material and Methods: Review of medical records of patients with gallbladder cancer in an oncology service. Results: Of 207 patients with gallbladder cancer, 15patients aged 53-72years, 93% women had an epidermoid component in their cancer. Forty percent were diabetic and 33% had cholelithiasis. All had locoregional extension of the tumor. A cholecystectomy was done in nine patients (using open surgery in six). In six patients, only a biopsy was done. Median survival was 4.2 months. Conclusions: Gallbladder epidermoid carcinoma is uncommon and has a bad prognosis.


Subject(s)
Humans , Male , Female , Middle Aged , Carcinoma, Squamous Cell/mortality , Gallbladder Neoplasms/mortality , Prognosis , Carcinoma, Squamous Cell/blood , Carcinoma, Squamous Cell/therapy , Survival Analysis , Retrospective Studies , Gallbladder Neoplasms/blood , Gallbladder Neoplasms/therapy
12.
Rev. méd. Chile ; 146(10): 1205-1209, dic. 2018. graf
Article in Spanish | LILACS | ID: biblio-978757

ABSTRACT

Gastric squamous cell carcinoma (SCC) is a rare type of cancer. We report three patients with the tumor. A 65 years old male presenting with weight los and heartburn. An upper gastrointestinal endoscopy revealed an ulcerated tumor whose biopsy disclosed a gastric epidermoid carcinoma. The patient was operated and chemotherapy was attempted, but he died five months later. A 39 years old male with an antral tumor corresponding to an epidermoid carcinoma. He was operated and received chemotherapy and radiotherapy and died one year later. A 79 years old female with a distal antral tumor corresponding to a undifferentiated epidermoid carcinoma. She received palliative therapy and died two months later.


Subject(s)
Humans , Male , Female , Adult , Aged , Stomach Neoplasms/pathology , Carcinoma, Squamous Cell/pathology , Stomach Neoplasms/therapy , Biopsy , Carcinoma, Squamous Cell/therapy , Fatal Outcome
13.
Rev. bras. cir. plást ; 33(1): 130-134, jan.-mar. 2018. ilus
Article in English, Portuguese | LILACS | ID: biblio-883649

ABSTRACT

A hemicorporectomia ou amputação translombar foi primeiramente descrita em 1950 por Kredel como método curativo para neoplasia localmente avançada de pelve. Trata-se de um procedimento cirúrgico extenso, que quando bem indicado é capaz de prover a cura oncológica, além de possibilitar a melhora clínica e de qualidade de vida. Os autores apresentam o relato de caso de um paciente de 34 anos, com carcinoma espinocelular em úlcera de pressão crônica, acometendo períneo, glúteo e coxa posterior à direita. O paciente foi submetido à hemicorporectomia com reconstrução utilizando retalho subtotal da coxa esquerda. Observou-se boa evolução no pós-operatório e a utilização do retalho subtotal da coxa para fechamento da hemicorporectomia se mostrou como método seguro, eficiente e de técnica reprodutível.


Hemicorporectomy or translumbar amputation was first described in 1950 by Kredel to treat locally advanced pelvic neoplasia. This extensive surgical procedure can achieve oncological cure and improve clinical status and quality of life. The authors present a case report of a 34-yearold patient with squamous cell carcinoma in a chronic pressure ulcer affecting the right perineum, gluteus, and posterior thigh. The patient underwent hemicorporectomy with reconstructive surgery using a partial-thickness flap of the left thigh. The postoperative course was good, and the use of a partial-thickness flap of the thigh to close the hemicorporectomy proved to be safe, efficient, and reproducible.


Subject(s)
Humans , Male , Adult , History, 21st Century , Osteomyelitis , Paraplegia , Surgical Flaps , Carcinoma, Squamous Cell , Reconstructive Surgical Procedures , Pressure Ulcer , Hip , Amputation , Osteomyelitis/surgery , Osteomyelitis/therapy , Paraplegia/surgery , Paraplegia/complications , Paraplegia/diagnosis , Surgical Flaps/surgery , Surgical Flaps/adverse effects , Carcinoma, Squamous Cell/surgery , Carcinoma, Squamous Cell/complications , Carcinoma, Squamous Cell/therapy , Reconstructive Surgical Procedures/methods , Pressure Ulcer/surgery , Pressure Ulcer/physiopathology , Hip/surgery , Amputation/methods
14.
Rev. otorrinolaringol. cir. cabeza cuello ; 77(4): 417-424, dic. 2017. ilus
Article in Spanish | LILACS | ID: biblio-902797

ABSTRACT

El objetivo de este caso es profundizar en el conocimiento del cáncer de lengua en pacientes jóvenes. Se trata de un caso clínico: Mujer de 17 años sin antecedentes ni hábitos tóxicos, que acude por presentar tumoración en hemilengua izquierda con biopsia de carcinoma escamoso. En TAC: Lesión en hemilengua izquierda que afecta al suelo de la boca. Adenopatías bilaterales. Estadío IVA. Se decide quimioterapia de inducción seguido de quimioradioterapia. Presentó recidiva tras 5 meses de seguimiento, y se realizó glosectomía parcial. Tras 12 meses libre de enfermedad presentó nueva recidiva local que se intervino quirúrgicamente. Actualmente en seguimiento y sin signos de enfermedad. Existen estudios que indican que la prevalencia del cáncer de cabeza y cuello está aumentando en pacientes jóvenes; comportándose de forma diferente entre unos grupos de edad y otros. Concluimos que los factores epidemiológicos, genéticos, etiológicos y clinicopatológicos de los pacientes jóvenes con cáncer de cabeza y cuello sugieren una divergencia biológica frente a lo que ocurre con dichos cánceres en pacientes añosos. La mejora del conocimiento de la biología molecular es necesaria para establecer el éxito en la prevención y el tratamiento de dichos pacientes.


To delve into the knowledge of tongue cancer in young patients. Case We presented a 17 years-old female, without tobacco and alcohol exposure, referred to Oral and Maxillofacial department with a squamous cell carcinoma in the tongue with bilateral cervical metastasis. We decided, in a multidisciplinary team, to treat her with chemotherapy followed by chemoradiotherapy. She had two local recurrences 5 and 12 months after the treatment which we treated with surgery both. Afher that, we follow her every month and she is without recurrences. Several reports suggest increasing incidence trends of head and neck cancer in young patients, disproportional to the patients above 45 years old. Moreover, the majority of young non-smoking non-drinking head and neck cancer patients is female. This disparity suggests that the pathogenesis of head and neck cancer in young patients differs from head and neck cancer development in old patients. Conclusion: The unique epidemiologic, genetic, etiologic, and clinicopatho- logic characteristics of young-onset HNSCC suggests a divergent biology from HNSCC occurring in older patients. Improved definition of this biology is needed to establish successful preventive and treatment de intensification efforts.


Subject(s)
Humans , Female , Adolescent , Mouth Neoplasms/therapy , Mouth Neoplasms/diagnostic imaging , Carcinoma, Squamous Cell/therapy , Carcinoma, Squamous Cell/diagnostic imaging , Mouth Neoplasms/pathology , Carcinoma, Squamous Cell/pathology , Combined Modality Therapy , Neoplasm Recurrence, Local/surgery
15.
Appl. cancer res ; 37: 1-9, 2017. tab, ilus
Article in English | LILACS, Inca | ID: biblio-912210

ABSTRACT

Background: It is expected that about 65,000 new patients will be diagnosed with head and neck cancer in 2017 in the United States. Patients with recurrent or advanced or metastatic head and neck do not have good survival due to aggressive and recurrent nature of this cancer. Moreover, cumulative and residual toxicities from previous and ongoing treatments significantly impede quality of remaining part of their life. Currently available chemotherapeutic regimens for this group are derived from the treatments used for the potentially curable disease. These regimens and associated toxicity are obviously not the best matches for the treatment with palliative intent. We here present a retrospective study where we used dose-adjusted chemotherapy specifically for palliative treatment this sub-group of head and neck cancer patients. Methods: Study population was identified from the University of Florida, and IRB approval was obtained. We used currently available and approved chemotherapeutic agents (including Taxols, Platins, 5-Fluorouracil and Epidermal Growth Factor Receptor inhibitors) for treatment of head and neck cancer but dose-adjusted at approximate 50% dose of currently recommended doses. We then gave personalized doses for a prolonged period by titrating doses based on response and tolerability of each patient. Data was collected for treatment, response, side effects, and outcomes. KM analysis was performed for survival data. Results: Total of 32 patients were included in this study with a median age of 65.2 years and a median follow-up of 10.1 months. 62.5% (n = 20) had locally advanced disease and rest had metastatic disease. 37.5% (n = 12) had new disease while rest had recurrent cancer. Of 32 patients, 14 patients received TPF based while 18 patients received PFE based chemotherapy. Total of 270 chemotherapy cycles were delivered among these 32 patients. They received a median of 9 cycles (range 3­14) over a median of 6.2 months (range 1.8­21.1). With this treatment approach, we noted median progression-free survival of 14.0 months and median overall survival of 15.7 months. Notable grade 3 toxicities were generalized fatigue in 12.5% (n = 4), nausea/vomiting in 6.3% (n = 2), diarrhea in in 6.3% (n = 2), mouth soreness in 6.3% (n = 2), rash in 3.1% (n = 1), neutropenia in 18% (n = 6) and anemia in 15.6% (n = 5) while notable grade 4 toxicities were neutropenia and anaphylaxis in 3.1% (n = 1) patient each (AU)


Subject(s)
Humans , Male , Female , Palliative Care , Recurrence , Carcinoma, Squamous Cell/therapy , Drug Therapy , Administration, Metronomic , Head and Neck Neoplasms/drug therapy , Antineoplastic Agents
16.
Appl. cancer res ; 37: 1-8, 2017. tab, ilus
Article in English | LILACS, Inca | ID: biblio-912717

ABSTRACT

Background: The development of oral cavity cancer is related to the accumulation of genetic alterations. The activation of AKT is associated with the proliferation and progression of many malignancies. It is thought that MAP kinases, together with the PI3K/AKT/mTOR signaling pathway, promote uncoordinated proliferation via inhibition of PTEN, thus increasing cell survival and mediating cancer progression. However, there are few studies regarding the expression of these proteins in oral squamous cell carcinoma (SCC). Methods: The expression of PI3K, p-mTOR, p-AKT, p-MAPK, and PTEN in 125 oral SCCs, including gingival, palate hard, and alveolar ridge tumors, was examined by immunohistochemistry and correlated with clinicopathological data and survival rates. Results: We observed PI3K, p-mTOR, p-MAPK, p-AKT, and PTEN positive staining in the cytoplasm of most SCC (92.4%, 88.2%, 88.3%, 94.2%, and 25%, respectively). Positive nuclear staining was observed for p-mTOR, PTEN, p-AKT, and p-MAPK (42.9%, 72%, 64.2%, and 58.2%, respectively). Only p-mTOR protein expression was observed on the cell membrane and was present in 44.5% of cases. A statistically significant correlation was found between p-MAPK expression and SCC clinicopathological stages III and IV (p = 0.0042). Lower rates of disease-free survival were found in patients with SCC III / IV (p = 0.001). Patients with positive nuclear staining of p-mTOR displayed a significant increase in disease-free survival rates. Discussion: The identification of prognostic and predictive markers is clinically important because oral cancer is a group of heterogeneous diseases with various biological and clinical characteristics. Conclusion: Our findings suggest that the PI3K/AKT pathway is activated in gingival, hard palate, and alveolar ridge SCCs. We have demonstrated that p-mTOR expression can function as a biomarker for survival in oral SCCs and could be a promising therapeutic target in oral SCC treatment (AU)


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Prognosis , Mouth Neoplasms/diagnosis , Immunohistochemistry , Carcinoma, Squamous Cell/therapy , Biomarkers, Tumor , Phosphatidylinositol 3-Kinases , PTEN Phosphohydrolase , Aurora Kinase C
17.
Article in Spanish | LILACS | ID: biblio-908134

ABSTRACT

Introducción: entre las diferentes modalidades terapéuticas para el carcinoma escamoso de laringe en estadios iniciales, la cirugía transoral láser (CTL) constituye el tratamiento de elección. El láser de CO2 es aceptado universalmente como la mejor herramienta terapéutica en este sentido. En situaciones de no poder acceder a esa tecnología, es posible utilizar otros instrumentos para resección en CTL (radiofrecuencia, electrobisturí). Entre estas, nuestro equipo de trabajo ha implementado el uso del láser de diodo de 1470 nm. En el presente trabajo describimos los resultados preliminares en el tratamiento de estadios tempranos del carcinoma escamoso de laringe con CTL. Materiales y métodos: Se utilizó el láser de diodo de 1470 nm en pacientes adultos mayores realizados entre enero de 2012 y diciembre de 2015 en el Servicio de Otorrinolaringología del Hospital Dr. C. Milstein. Resultados: Se trataron 32 pacientes con cáncer de laringe, de los cuales se incluyeron 21, todos mayores de 65 años, con carcinoma escamoso de laringe estadio Tis T1 y T2 sin compromiso cervical ni metastásico y sin tratamiento oncológico previo. De los 21 pacientes incluidos, a 19 se les realizó una única intervención y dos fueron reintervenidos con la misma técnica. Conclusiones: El uso del láser diodo de 1470 nm para el tratamiento del carcinoma escamoso de laringe en estadios iniciales ha permitido controlar la enfermedad en los 21 pacientes intervenidos con esta tecnología, en un tiempo medio de seguimiento de 21 meses. La CTL con láser de diodo se presenta como una opción válida para el tratamiento del cáncer de laringe en estadios iniciales.


Introduction: among the different therapeutic modalities for squamous carcinoma of the larynx in early stages, transoral laser surgery (CTL) is the treatment of choice. Materials and methods: CO2 laser is universally accepted as the best therapeutic tool in this regard. In situations of not being able to access that technology, it is possible to use other CTL resection instruments (radiofrequency, electro-scalpel). Among these, our work team has implemented the use of 1470 nm diode laser. In the present work we describe the preliminary results in the treatment of early stages of squamous carcinoma of the larynx with CTL using 1470 nm diode laser in elderly patients performed between January 2012 and December 2015 at the Otorhinolaryngology Service of Dr. Hospital C. Milstein. Results: Thirty-two patients with laryngeal cancer were treated, including 21, all over 65 years old, with squamous carcinoma of the Tis T1 and T2 larynx without cervical or metastatic involvement and without prior cancer treatment. Of the 21 patients included, 19 were given a single intervention and two were retreated with the same techniqu Conclusions: The use of laser 1470 nm diode for the treatment of squamous carcinoma of the larynx in early stages has allowed the control of the disease in the 21 patients operated with this technology, in an average follow-up time of 21 months. The CTL with diode laser is presented as a valid option for the treatment of laryngeal cancer in initial stages.


Introdução: entre os vários tratamentos para o carcinoma de células escamosas da laringe em modalidades estágios iniciais, laser cirurgia transoral (CTL) é o tratamento de escolha. O laser de CO2 é universalmente aceito como a melhor ferramenta terapêutica a este respeito. Em situações de não ter acesso a essa tecnologia, é possível usar outros instrumentos para CTL ressecção (radiofreqüência, eletrocautério). Materiais e métodos: Entre estes, a nossa equipa implementou o uso de diodo laser 1470 nm. Neste artigo descrevemos os resultados preliminares no tratamento do carcinoma de células escamosas da laringe, com CTL estágios iniciais utilizando o laser de diodo 1470 nm em pacientes idosos realizadas entre Janeiro de 2012 e Dezembro de 2015, Otorrinolaringologia do Hospital Dr. C. Milstein. Resultados: 32 pacientes com câncer de laringe, das quais 21 foram incluídos, todos com mais de 65 anos com carcinoma epidermóide de laringe Tis T1 e T2 sem ou compromisso de cancro cervical metastático e sem tratamento foram tratados. Dos 21 pacientes incluídos, 19 pacientes foram submetidos a uma única intervenção e dois eram reintevenidos com a mesma técnica. Conclusão: O uso de 1.470 nm diodo laser para o tratamento de carcinoma de células escamosas da laringe em estágios iniciais ajudou a controlar a doença em 21 pacientes tratados com esta tecnologia, em um seguimento médio de 21 meses. CTL diodo laser é apresentado como uma opção válida para o tratamento de carcinoma da laringe, em fases iniciais.


Subject(s)
Male , Female , Humans , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/surgery , Carcinoma, Squamous Cell/therapy , Laryngeal Neoplasms/surgery , Laryngeal Neoplasms/therapy , Lasers, Gas/therapeutic use , Lasers, Semiconductor/therapeutic use
18.
An. bras. dermatol ; 91(6): 799-802, Nov.-Dec. 2016. tab, graf
Article in English | LILACS | ID: biblio-837989

ABSTRACT

Abstract Squamoid eccrine ductal carcinoma is an eccrine carcinoma subtype, and only twelve cases have been reported until now. It is a rare tumor and its histopathological diagnosis is difficult. Almost half of patients are misdiagnosed as squamous cell carcinoma by the incisional biopsy. We report the thirteenth case of squamoid eccrine ductal carcinoma. Female patient, 72 years old, in the last 6 months presenting erythematous, keratotic and ulcerated papules on the nose. The incisional biopsy diagnosed squamoid eccrine ductal carcinoma. After excision, histopathology revealed positive margins. A wideningmargins surgery and grafting were performed, which again resulted in positive margins. The patient was then referred for radiotherapy. After 25 sessions, the injury reappeared. After another surgery, although the intraoperative biopsy showed free surgical margins, the product of resection revealed persistent lesion. Distinction between squamoid eccrine ductal carcinoma and squamous cell carcinoma is important because of the more aggressive nature of the first, which requires wider margins surgery to avoid recurrence.


Subject(s)
Humans , Aged , Sweat Gland Neoplasms/pathology , Carcinoma, Ductal/pathology , Eccrine Glands/pathology , Sweat Gland Neoplasms/therapy , Biopsy , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/therapy , Nose/pathology , Carcinoma, Ductal/therapy , Neoplasm Recurrence, Local
19.
Rev. otorrinolaringol. cir. cabeza cuello ; 76(2): 209-214, ago. 2016. ilus, tab
Article in Spanish | LILACS | ID: lil-793968

ABSTRACT

El carcinoma escamoso de conducto auditivo externo es poco frecuente. La sintomatología puede semejar una otitis externa u otitis media crónica, lo que puede retrasar el diagnóstico. La falta de un sistema de clasificación y el número limitados de casos hace difícil la elaboración de guías de tratamiento. Se describe una serie de casos de esta neoplasia, asf como una revisión de la literatura actual.


Squamous cell carcinoma of the external auditory canal is rare. The symptoms may resemble an external otitis or chronic otitis media, which can delay diagnosis. The lack of a classification system and the limited number of cases makes it difficult the development of treatment guidelines. We present a case series of this neoplasia, as well as a review of the literature.


Subject(s)
Humans , Male , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/therapy , Ear Neoplasms/diagnosis , Ear Neoplasms/therapy , Ear, External , Carcinoma, Squamous Cell/pathology , Ear Neoplasms/pathology , Temporal Bone
20.
Säo Paulo med. j ; 133(6): 480-487, Nov.-Dec. 2015. tab, graf
Article in English | LILACS | ID: lil-770154

ABSTRACT

ABSTRACT CONTEXT AND OBJECTIVE: Worldwide, there is no single strategy for optimal management of patients with ASCUS (atypical squamous cells of undetermined significance) cytology reports. The objective of this study was to determine the kind of clinical management conducted among women with a first ASCUS Pap smear report. DESIGN AND SETTING: Prospective single cohort study at a cervical pathology unit in Santiago, Chile. METHODS: This was an epidemiological, descriptive, observational and quantitative follow-up study on a cohort of women with ASCUS cytological reports. RESULTS: In the screening phase, 92,001 cervical cytological smears were collected in primary healthcare clinics. In the diagnostic phase, all women with a first ASCUS report were selected (n = 446). These women were asked to undergo the Pap test again and it was found that 301 women had normal results, 62 women had abnormal results and 83 did not repeat the test. In the diagnostic confirmation phase, the 62 women with abnormal results underwent colposcopy and, from these results, 58 of them underwent a biopsy. The results from the biopsies showed that 16 women had negative histological reports, 13 had CIN 1 and 29 had CIN 2+. In the treatment phase, the 42 women with lesions underwent a variety of treatments, according to the type of lesion. In the post-treatment phase, cytological and colposcopic monitoring was instituted. CONCLUSION: The clinical management consisted of traditional management of screening, diagnosis, diagnostic confirmation, treatment and post-treatment monitoring.


RESUMO CONTEXTO E OBJETIVO: Mundialmente, não existe estratégia única para o gerenciamento ideal de pacientes com laudos de citologia ASCUS ( atypical squamous cells of undetermined significance ). O objetivo do estudo foi determinar o tipo de gerenciamento clínico realizado em mulheres com o primeiro laudo de Papanicolaou ASCUS. DESENHO E LOCAL: Estudo prospectivo de coorte única em uma unidade de patologia cervical em Santiago, Chile. MÉTODOS: Estudo epidemiológico, descritivo, observacional e quantitativo de seguimento de um grupo de mulheres com laudos de citologia ASCUS. RESULTADOS: Na fase de rastreamento, 92.001 relatórios de citologia cervical foram coletados nos ambulatórios da rede pública de saúde. Na fase de diagnóstico, foi selecionada a totalidade de mulheres com relatórios citológicos de ASCUS (n = 446). Essas mulheres foram submetidas a repetição do exame de Papanicolaou, obtendo-se 301 mulheres com resultados normais, 62 mulheres com resultados anormais e 83 que não repetiram o exame. Na fase de confirmação de diagnóstico, as 62 mulheres com resultados anormais foram submetidas a colposcopia e, considerando-se os resultados obtidos, 58 foram submetidas a biópsia. Os resultados das biópsias mostraram 16 mulheres com laudos histológicos negativos, 13 com NIC 1 e 29 com NIC 2 +. Na fase terapêutica, as 42 mulheres com lesões foram submetidas a diversos tratamentos de acordo com o tipo de lesão. Para a fase pós-tratamento, foi instituído um sistema de monitoramento citocolposcópico. CONCLUSÃO: As condutas clínicas tiveram gestão tradicional de rastreamento, diagnóstico, confirmação diagnóstica, tratamento e acompanhamento pós-tratamento.


Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Young Adult , Atypical Squamous Cells of the Cervix/pathology , Cervical Intraepithelial Neoplasia/pathology , Cervical Intraepithelial Neoplasia/therapy , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/therapy , Chile , Colposcopy , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/therapy , Disease Management , Follow-Up Studies , Neoplasm Staging , Papanicolaou Test , Prospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL